Skip to main content

A tale of two pharmas: Can obesity firms continue their outperformance in 2024?

By The Wall Street Journal  
   December 28, 2023

Obesity and diabetes companies soared this year, while the rest of pharma did poorly.

Full story


Get the latest on healthcare leadership in your inbox.